AbbVie, Others Move To End Generic Bystolic Antitrust Claims

By Khorri Atkinson · February 9, 2021, 10:42 PM EST

AbbVie Inc. and subsidiaries have fired back against a consolidated class action accusing the drug giant of reaping millions of dollars in profit by paying competitors to delay generic forms of...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

In re Bystolic Antitrust Litigation

Case Number

Court

New York Southern

Nature of Suit

Anti-Trust

Date Filed

July 23, 2020

Recent Articles By Khorri

July 28, 2022
Judge Mulls Feds', Tobacco Cos.' Decree On Health Warnings
July 01, 2022
Ky. Trial Judge Vacancy Tees Up Likely Biden-McConnell Deal
June 10, 2022
Fed. Circ. Eyes Eligibility Of Stanford's Transplant Testing IP
May 25, 2022
11th Circ. Nixes Suit By Atty Who Ended Mental Health Checks
May 23, 2022
Judge Skeptically Probes Fate Of FDA's Cigar Regulation
May 16, 2022
Providers Say 9th Circ. Ruling Helps BCBS Antitrust Case
April 11, 2022
DOJ Attys Escape Subpoena To Testify In Wage-Fixing Trial
March 24, 2022
Endo Wins Dismissal Of FTC's Suit Over Impax Opioid Deal
March 22, 2022
3rd Circ. Upholds FTC Bid To Pause NJ Hospital Merger
March 18, 2022
DC Judge Ends 'Dormant' LabMD Suit Against FTC Attys